ABSTRACT
PATIENTS AND METHODS: A prospective registration of patients with colorectal cancer and a colonoscopy within the last 10 years. We tried to classify these post-colonoscopy colorectal cancers (PCCRCs) by most reasonable explanation and into subcategories suggested by the World Endoscopy Organization (WEO) and calculated the unadjusted PCCRC rate. RESULTS: 47 PCCRCs were identified. The average age at diagnosis of PCCRC was 73 years. PCCRCs were more located in the right colon with a higher percentage of MSI-positive and B-RAF mutated tumours. The average period between index colonoscopy and diagnosis of PCCRC was 4.2 years. Sixty-eight % of all PCCRCs could be explained by procedural factors. The mean PCCRC-3y of our department was 2.46%. CONCLUSIONS: The data of our centre are in line with the data of the literature from which can be concluded that most postcolonoscopy colorectal cancers are preventable. The PCCRC-3y is an important quality measure for screening colonoscopy. Ideally all centres involved in the population screening should measure the PCCRC-3 y annually, with cooperation of the cancer registry and reimbursement data provided by the Intermutualistic Agency (IMA).
Subject(s)
Colorectal Neoplasms , Colonoscopy , Colorectal Neoplasms/diagnosis , Colorectal Neoplasms/epidemiology , Humans , Prospective Studies , Risk Factors , Time FactorsABSTRACT
OBJECTIVE: To determine variation in diagnostic strategies for diagnosing dementia between Dutch hospitals. DESIGN: Descriptive, retrospective research based on claim data of Dutch health insurers. METHOD: Information on the use of diagnostic ancillary services carried out from 2015 to 2018 was collected via national-level insurance claims for patients who received a (new) diagnose-coding for dementia in 2018. Hospitals were included in the analysis if they diagnosed >50 patients with dementia. We distinguished academic medical centres (AMC), non-academic training hospitals (TH) and general hospitals (GH). RESULTS: In 2018, 20.073 new cases of dementia were diagnosed in 71 hospitals. The percentages of patients undergoing MRI/CT-imaging ranged from 37 to 99% (median 76.7%), neuropsychological-assessment from 0-89% (median 31.8%), cerebrospinal fluid examination from 0-14% (median 2.4%), PET/SPECT-imaging from 0-16% (median 6.2%) and electroencephalography from 1-20% (median 5.8%). Practice variation was comparable in AMCs, THs and GHs and was evidently skewed for PET/SPECT-imaging, electroencephalography and cerebrospinal fluid examination. There were no distinct differences according to case-mix characteristics or hospital volume. The percentage of patients subjected to ancillary diagnostic investigations decreased sharply with increasing age. CONCLUSION: In the Netherlands, diagnostic ancillary methods used vary widely between hospitals both in frequency and modality. This variation may be driven by limited evidence of diagnostic accuracy and added value of different diagnostic tests, variations in doctor and patient preferences and differences in available diagnostic techniques per hospital. Further exploration of this heterogeneity may help to identify a strategy that combines the most benefit with the least burden.
Subject(s)
Dementia/diagnosis , Diagnostic Tests, Routine/methods , Hospitals , Mass Screening/methods , Practice Patterns, Physicians' , Cerebrospinal Fluid , Electroencephalography , Female , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Netherlands , Neuropsychological Tests , Positron-Emission Tomography , Retrospective Studies , Tomography, Emission-Computed, Single-PhotonABSTRACT
A 50-year-old patient was admitted to our department after developing severe abdominal cramps, watery diarrhea and fever, during four days whilst travelling abroad. Imaging identified a mass in the ascending colon with simultaneous liver lesions. Initially a diagnosis of metastatic colorectal cancer was suggested, however colonoscopy showed a large lesion with a central ulcer and surrounding inflammation in the ascending colon. Biopsies confirmed our clinical suspicion of amoebic colitis, complicated by development of an amoeboma and simultaneous liver abscesses. Amoeboma formation is a rare complication of amoebiasis, however a simultaneous presentation with liver abscesses, amoebic colitis and an amoeboma might even be less frequent. Despite its rarity physicians should maintain a high index of suspicion of patients presenting with synchronous liver and colon lesions, especially as travel to endemic areas has increased.
Subject(s)
Amebiasis , Colonoscopy/methods , Dysentery, Amebic/diagnosis , Entamoeba histolytica/isolation & purification , Liver Abscess, Amebic/diagnosis , Abdominal Pain/parasitology , Biopsy , Dysentery, Amebic/parasitology , Dysentery, Amebic/surgery , Humans , Liver Abscess, Amebic/parasitology , Liver Abscess, Amebic/surgery , Liver Neoplasms/diagnosis , Middle AgedABSTRACT
Pelvic gynecological malignancies account for 6% of all cancers. In the relapsed state, classical treatments are limited. There is an urgent need for new and personalized treatment. Wilms' tumor gene 1 (WT1) is the most important tumor-associated antigen. Although highly present in gynecological tumors, active immunotherapy against it is still underexplored. This review gives an insight into the importance of WT1 in pelvic gynecological malignancies and the first taken steps into the world of WT1 immunotherapy.
Subject(s)
Antigens, Neoplasm/immunology , Genital Neoplasms, Female , Immunotherapy , Pelvic Neoplasms , WT1 Proteins/immunology , Female , Genital Neoplasms, Female/immunology , Genital Neoplasms, Female/pathology , Genital Neoplasms, Female/therapy , Humans , Pelvic Neoplasms/immunology , Pelvic Neoplasms/pathology , Pelvic Neoplasms/therapyABSTRACT
BACKGROUND AND PURPOSE: Pseudoprogression is a frequent phenomenon observed since the introduction of postoperative therapy with radiotherapy and temozolomide (RT/TMZ) in glioblastoma multiforme (GBM) patients. However, the criteria defining pseudoprogression, its incidence, the time of occurrence and its impact on therapy and outcome remain poorly defined. METHODS: The objective of this study is to compare two sets of criteria (liberal and stringent), defining pseudoprogression, in a cohort of patients treated before and after the introduction of RT/TMZ in the standard postoperative treatment. This retrospective review includes 136 unselected and consecutively treated patients with pathologically diagnosed GBM. RESULTS: Pseudoprogression was observed in 10 (12%) cases applying the stringent criteria, and in 18 (23%) patients when using the liberal criteria, in the cohort treated with RT/TMZ. Pseudoprogression was observed in only one patient treated with RT alone. The median time to pseudoprogression was 4 weeks after the end of RT. Patients with pseudoprogression had a median survival time of 28 months, compared with 12 months for patients without pseudoprogression. CONCLUSIONS: The incidence of pseudoprogression after RT/TMZ strongly depends on the applied criteria. However, regardless of the stringency of the criteria, the impact on survival remains the same.
Subject(s)
Brain Neoplasms/pathology , Brain/pathology , DNA Modification Methylases/genetics , DNA Repair Enzymes/genetics , Glioblastoma/pathology , Radiation Injuries/diagnosis , Tumor Suppressor Proteins/genetics , Adolescent , Adult , Aged , Aged, 80 and over , Antineoplastic Agents/administration & dosage , Brain Neoplasms/mortality , Brain Neoplasms/therapy , Chemoradiotherapy , DNA Methylation , Dacarbazine/administration & dosage , Dacarbazine/analogs & derivatives , Female , Glioblastoma/mortality , Glioblastoma/therapy , Humans , Incidence , Kaplan-Meier Estimate , Male , Middle Aged , Promoter Regions, Genetic/genetics , Radiation Injuries/epidemiology , Retrospective Studies , Risk Factors , Temozolomide , Young AdultABSTRACT
We report a case of an 80-year-old female with dysphagia lusoria caused by oesophageal compression by a right-sided atheromatous aorta. The relationship between aortic root vascular anomalies and dysphagia has been clearly established in literature and can be diagnosed by a barium swallowing study, followed by CT or MRI. Aortic anomalies and variations in aortic branches are caused by embryonic malformations and are mostly described in association with congenital heart lesions. In this pauci-symptomatic patient, the preferred treatment is a conservative management.
Subject(s)
Aorta/abnormalities , Deglutition Disorders/etiology , Aged, 80 and over , Aortography , Deglutition Disorders/diagnostic imaging , Female , HumansABSTRACT
OBJECTIVE: The development of osteoarthritis (OA) may be caused by activation of hypertrophic differentiation of articular chondrocytes. Healthy articular cartilage is highly resistant to hypertrophic differentiation, in contrast to other hyaline cartilage subtypes, such as growth plate cartilage. The purpose of this study was to elucidate the molecular mechanism responsible for the difference in the propensity of human articular cartilage and growth plate cartilage to undergo hypertrophic differentiation. METHODS: Whole-genome gene-expression microarray analysis of healthy human growth plate and articular cartilage derived from the same adolescent donors was performed. Candidate genes, which were enriched in the articular cartilage, were validated at the messenger RNA (mRNA) and protein levels and examined for their potential to inhibit hypertrophic differentiation in two models. In addition, we studied a possible genetic association with OA. RESULTS: Pathway analysis demonstrated decreased Wnt signaling in articular cartilage as compared to growth plate cartilage. This was at least partly due to increased expression of the bone morphogenetic protein and Wnt antagonists Gremlin 1, Frizzled-related protein (FRP), and Dkk-1 at the mRNA and protein levels in articular cartilage. Supplementation of these proteins diminished terminal hypertrophic differentiation without affecting chondrogenesis in long-bone explant cultures and chondrogenically differentiating human mesenchymal stem cells. Additionally, we found that single-nucleotide polymorphism rs12593365, which is located in a genomic control region of GREM1, was significantly associated with a 20% reduced risk of radiographic hip OA in 2 population-based cohorts. CONCLUSION: Taken together, our study identified Gremlin 1, FRP, and Dkk-1 as natural brakes on hypertrophic differentiation in articular cartilage. As hypertrophic differentiation of articular cartilage may contribute to the development of OA, our findings may open new avenues for therapeutic intervention.
Subject(s)
Cartilage, Articular/metabolism , Glycoproteins/metabolism , Homeostasis/genetics , Intercellular Signaling Peptides and Proteins/metabolism , Adolescent , Animals , Cartilage, Articular/cytology , Child , Chondrocytes/cytology , Chondrocytes/metabolism , Gene Expression Profiling , Genome-Wide Association Study , Glycoproteins/genetics , Growth Plate/metabolism , Humans , Intercellular Signaling Peptides and Proteins/genetics , Intracellular Signaling Peptides and Proteins , MiceABSTRACT
OBJECTIVE: To assess the long-term effect of prepubertal high-dose GH treatment on growth in children with idiopathic short stature (ISS). DESIGN AND METHODS: Forty children with no signs of puberty, age at start 4-8 years (girls) or 4-10 years (boys), height SDS <-2.0 SDS, and birth length >-2.0 SDS, were randomly allocated to receive GH at a dose of 2 mg/m(2) per day (equivalent to 75 microg/kg per day at start and 64 microg/kg per day at stop) until the onset of puberty for at least 2 years (preceded by two 3-month periods of treatment with low or intermediate doses of GH separated by two washout periods of 3 months) or no treatment. In 28 cases, adult height (AH) was assessed at a mean (S.D.) age of 20.4 (2.3) years. RESULTS: GH-treated children (mean treatment period on high-dose GH 2.3 years (range 1.2-5.0 years)) showed an increased mean height SDS at discontinuation of the treatment compared with the controls (-1.3 (0.8) SDS versus -2.6 (0.8) SDS respectively). However, bone maturation was significantly accelerated in the GH-treated group compared with the controls (1.6 (0.4) versus 1.0 (0.2) years per year, respectively), and pubertal onset tended to advance. After an untreated interval of 3-12 years, AH was -2.1 (0.7) and -1.9 (0.6) in the GH-treated and control groups respectively. Age was a positive predictor of adult height gain. CONCLUSION: High-dose GH treatment restricted to the prepubertal period in young ISS children augments height gain during treatment, but accelerates bone maturation, resulting in a similar adult height compared with the untreated controls.
Subject(s)
Body Height/drug effects , Human Growth Hormone/administration & dosage , Body Mass Index , Bone Development/drug effects , Child , Child, Preschool , Female , Follow-Up Studies , Humans , Linear Models , Male , Netherlands , Puberty , Young AdultABSTRACT
We have successfully treated over two hundred high-grade glioma (HGG) patients with immunotherapy consisting of vaccination with autologous dendritic cells (DCs) loaded with autologous tumour lysate. It has been documented that regulatory T cells (Treg) can counteract anti-tumour immune responses. Therefore, monitoring of Treg in these patients is essential. Up till now, Treg have been characterized based on the expression of the transcription factor Foxp3. Here, we validated IL-7 receptor alpha subunit (CD127)dim expression as a marker for human Treg within HGG patients, as a less laborious assay for routine use in tumour vaccination trials. We noted a strong positive correlation between Foxp3 expression and CD127dim expression in CD4+CD25+ and CD4+ cells. The suppressive function of CD4+CD127dim cells was assessed in an allogeneic mixed lymphocyte reaction (MLR). We conclude that CD127 staining is a fast, well-suited and reproducible Treg monitoring tool in HGG patients treated with immunotherapy.
Subject(s)
Biomarkers/metabolism , Cancer Vaccines , Central Nervous System Neoplasms/immunology , Glioma/immunology , Interleukin-7 Receptor alpha Subunit/metabolism , T-Lymphocyte Subsets/metabolism , T-Lymphocytes, Regulatory/metabolism , Antigens, Neoplasm/immunology , Antigens, Neoplasm/metabolism , CD4 Antigens/biosynthesis , Cells, Cultured , Central Nervous System Neoplasms/blood , Central Nervous System Neoplasms/diagnosis , Central Nervous System Neoplasms/therapy , Dendritic Cells/immunology , Dendritic Cells/metabolism , Forkhead Transcription Factors/biosynthesis , Glioma/blood , Glioma/diagnosis , Glioma/therapy , Humans , Interleukin-2 Receptor alpha Subunit/biosynthesis , Lymphocyte Culture Test, Mixed , Monitoring, Physiologic , T-Lymphocyte Subsets/immunology , T-Lymphocyte Subsets/pathology , T-Lymphocytes, Regulatory/immunology , T-Lymphocytes, Regulatory/pathology , Transplantation, AutologousABSTRACT
The value of bioluminescence imaging (BLI) for experimental cancer models has become firmly established. We applied BLI to the GL261 glioma model in the context of dendritic cell (DC) immunotherapy. Initial validation revealed robust linear correlations between in vivo, ex vivo and in vitro luciferase activity measurements. Ex vivo BLI demonstrated midline crossing and leakage of tumor cells. Orthotopically challenged mice followed with BLI showed an initial adaptation phase, after which imaging data correlated linearly with stereologically determined tumor dimensions. Transition from healthy to moribund state corresponded with an increasing in vivo flux but the onset of neurological deficit was clearly delayed compared to the onset of in vivo flux increase. BLI was implemented in prophylactic immunotherapy and imaging data were prognostic for therapy outcome. Three distinct response patterns were detected. Our data underscore the feasibility of in vivo BLI in an experimental immunotherapeutic setting in the GL261 glioma model.
Subject(s)
Brain Neoplasms/diagnosis , Brain Neoplasms/therapy , Dendritic Cells/immunology , Diagnostic Imaging/methods , Glioma/diagnosis , Glioma/therapy , Immunotherapy/methods , Luminescent Measurements , Animals , Antigens, Neoplasm/genetics , Antigens, Neoplasm/immunology , Cell Line, Tumor , Female , Flow Cytometry/methods , Linear Models , Luciferases/genetics , Mice , Mice, Inbred C57BL , Neoplasm Transplantation/methods , Reproducibility of Results , Survival Analysis , Time Factors , Transduction, Genetic/methodsABSTRACT
We report a patient presenting with bilateral lacrimal gland involvement and perioptic nerve sheath lesions due to Langerhans cell histiocytosis (LCH) invasion. LCH is a rare multisystemic disease characterized by a clonal proliferation of Langerhans cells. All organs may be involved with a clinical spectrum ranging from a solitary bone lesion to a severe life-threatening multisystem disease. Osteolytic orbital bone lesions with extension into the adjacent orbital soft tissues have been described. To our knowledge, lacrimal gland involvement has probably been described only once before. Perioptic nerve lesions are also very rare, having been described only three times before.
Subject(s)
Histiocytosis, Langerhans-Cell/pathology , Lacrimal Apparatus/pathology , Optic Nerve/pathology , Child, Preschool , Diagnosis, Differential , Humans , Magnetic Resonance Imaging , Male , Tomography, X-Ray ComputedABSTRACT
BACKGROUND: Recent observations in limited numbers of patients suggest a potential benefit of intrapyloric injection of botulinum toxin in the treatment of gastroparesis. AIM: To characterize the effect of botulinum toxin on solid and liquid gastric emptying and on meal-related symptoms. METHODS: In 20 gastroparesis patients (17 women, mean age 37 +/- 3 years, three diabetic and 17 idiopathic), gastric emptying for solids and liquids was measured before and one month after intrapyloric botulinum toxin 4 x 25 units. Before the meal and at 15-min intervals up to 240 min postprandially, the patient graded the intensity of six gastroparesis symptoms, and a meal-related severity score was obtained by adding all intensities. Data (mean +/- S.E.M.) were compared using paired Student's t-test. RESULTS: Treatment with botulinum toxin significantly enhanced solid (t(1/2) 132 +/- 16 vs. 204 +/- 35 min, P < 0.05) but not liquid (92 +/- 10 vs. 104 +/- 11 min, N.S.) emptying. This was accompanied by a significant decrease in cumulative meal-related symptom score (73.5 +/- 16.3 vs. 103 +/- 17.1 baseline, P = 0.01) as well as individual severity scores for postprandial fullness, bloating, nausea and belching (all P < 0.001, two-way anova). CONCLUSIONS: Botulinum toxin improves solid but not liquid gastric emptying in gastroparesis, and this is accompanied by significant improvement of several meal-related symptoms.
Subject(s)
Anti-Dyskinesia Agents/therapeutic use , Botulinum Toxins/therapeutic use , Gastroparesis/drug therapy , Adult , Female , Gastric Emptying/drug effects , Humans , Male , Postprandial Period/physiology , Treatment OutcomeABSTRACT
Patients with relapsed malignant glioma have a poor prognosis. We developed a strategy of vaccination using autologous mature dendritic cells loaded with autologous tumour homogenate. In total, 12 patients with a median age of 36 years (range: 11-78) were treated. All had relapsing malignant glioma. After surgery, vaccines were given at weeks 1 and 3, and later every 4 weeks. A median of 5 (range: 2-7) vaccines was given. There were no serious adverse events except in one patient with gross residual tumour prior to vaccination, who repetitively developed vaccine-related peritumoral oedema. Minor toxicities were recorded in four out of 12 patients. In six patients with postoperative residual tumour, vaccination induced one stable disease during 8 weeks, and one partial response. Two of six patients with complete resection are in CCR for 3 years. Tumour vaccination for patients with relapsed malignant glioma is feasible and likely beneficial for patients with minimal residual tumour burden.
Subject(s)
Astrocytoma/therapy , Cancer Vaccines/immunology , Cancer Vaccines/therapeutic use , Dendritic Cells/immunology , Glioblastoma/therapy , Neoplasm Recurrence, Local/therapy , Vaccination , Adjuvants, Immunologic , Adolescent , Adult , Aged , Astrocytoma/pathology , Astrocytoma/surgery , Brain Edema/etiology , Child , Combined Modality Therapy , Feasibility Studies , Female , Glioblastoma/pathology , Glioblastoma/surgery , Humans , Hypersensitivity, Delayed , Male , Middle Aged , Neoplasm Recurrence, Local/pathologySubject(s)
Autoimmune Diseases/drug therapy , Immunoglobulins, Intravenous/administration & dosage , Interleukin-10/biosynthesis , Adolescent , Adult , Autoimmune Diseases/metabolism , Child, Preschool , Humans , Infusions, Intravenous , Leukocytes, Mononuclear/drug effects , Middle Aged , RNA, Messenger/analysisABSTRACT
Inhibition of co-stimulatory signals for T cells by interrupting CD80/CD86-CD28 and CD40-CD154 interactions is a promising approach to prevent transplant rejection and to induce graft tolerance. However, this tolerizing treatment might affect T cell reactivity towards all the antigens to which the immune system is exposed during treatment. We addressed the question whether such inhibition of co-stimulatory ligands on human antigen presenting cells (APC) would affect T cell reactivity against a virus. This was tested in an in vitro system with freshly isolated human monocytes transduced with adenovirus (ad) containing either murine interferon-gamma (mIFN-gamma) or green fluorescent protein (GFP) as marker transgene. T cells co-cultured with transduced monocytes proliferated and produced cytokines. These 'primed' T cells had strong antiviral activity as they subsequently killed ad/GFP-transduced monocytes and reduced mIFN-gamma accumulation in coculture with ad/mIFN-transduced monocytes. However, if priming had occurred in the presence of blocking anti-CD40/CD80/CD86 MoAbs, generation of this antiviral activity was completely prevented. Moreover, T cells primed in the absence of co-stimulatory cells failed to proliferate upon restimulation with adenovirus-transduced monocytes. The results confirm that co-stimulatory signals from APC are required for efficient induction of antiviral T cell activity and point to a potential infectious risk of blocking co-stimulatory signals.
Subject(s)
Adenoviridae/immunology , Antigens, CD/immunology , CD40 Antigens/immunology , Membrane Glycoproteins/immunology , T-Lymphocytes/immunology , Adult , Antibodies, Blocking/immunology , Antigen-Presenting Cells/immunology , B7-1 Antigen/immunology , B7-2 Antigen , Biomarkers/analysis , Cell Division/immunology , Cells, Cultured , Enzyme-Linked Immunosorbent Assay , Female , Green Fluorescent Proteins , Humans , Immune Tolerance/immunology , Indicators and Reagents/analysis , Interferon-gamma/blood , Interleukin-13/blood , Luminescent Proteins/analysis , Lymphocyte Activation/immunology , Male , Middle Aged , Monocytes/immunology , Transduction, Genetic/methods , Transgenes/immunologyABSTRACT
Immunogenicity of recombinant adenoviral (Ad) vectors severely hampers the clinical development of gene therapy protocols using repeated vector administrations. Inhibition of costimulation by APCs was explored as a strategy to circumvent the immune response against Ad particles. This strategy was tested in rhesus monkeys, treated transiently with chimeric anti-human CD40 and anti-human CD86 antagonist monoclonal antibodies (MAbs) at the time of systemic administration of a recombinant Ad vector. After Ad vector administration in the absence of immunosuppressive treatment, transgene expression in the serum lasted about 3-4 weeks. All control animals developed a strong neutralizing antibody (NAb) response to the Ad particles, which totally prevented efficient administration of a second vector, as shown by the lack of transgene expression. Treatment with anti-CD40 and anti-CD86 chimeric MAbs delayed or blocked the development of a humoral response against Ad and the infiltration of CD8(+) lymphocytes into the liver. This resulted in (i) increased persistence of Ad-transduced cells after injection of a first vector encoding a nonimmunogenic transgene, and (ii) the possibility of readministering a second Ad vector with significant efficacy. In both respects, the combined blockade of CD40 and CD86 was more efficient than treatment with anti-CD40 alone. This study shows for the first time in non-human primates that blocking CD40 and CD86 costimulatory molecules represents a promising strategy to inhibit immune responses against an Ad vector injected systemically.
Subject(s)
Adenoviridae/immunology , Gene Transfer Techniques , Genetic Therapy/methods , Genetic Vectors/immunology , Adenoviridae/genetics , Animals , Antibodies, Monoclonal/immunology , Antibodies, Viral/biosynthesis , Antigens, CD/immunology , B7-2 Antigen , CD40 Antigens/immunology , CD8-Positive T-Lymphocytes/immunology , Female , Gene Expression Regulation/immunology , Genetic Vectors/administration & dosage , Humans , Immune Tolerance , Liver/immunology , Macaca mulatta , Male , Membrane Glycoproteins/antagonists & inhibitors , Membrane Glycoproteins/immunology , TransgenesABSTRACT
Desmoplastic infantile ganglioglioma is a rare intracranial tumor of early childhood with a usually excellent prognosis despite malignant features both radiologically and histologically. We present the case of a desmoplastic infantile ganglioglioma with histologically highly anaplastic features and both intracerebral and pial metastases. After partial resection the tumor was rapidly progressive and new metastases appeared. A combination of vincristine and carboplatinum was used according to the Low Grade Glioma Protocol of the International Society of Pediatric Oncology, with a temporary good response. When histologically characterized by highly anaplastic features, it seems the biologic behavior of this tumor remains uncertain. The aggressive behavior and the responsiveness to chemotherapy in this case may challenge the belief in the benign nature of these rare tumors.